Standout Papers
- Feasibility of a High-Flux Anticancer Drug Screen Using a Diverse Panel of Cultured Human Tumor Cell Lines (1991)
- Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. (1988)
- The NCI60 human tumour cell line anticancer drug screen (2006)
- Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. (1988)
Citation Impact
Citing Papers
Organic Cation Transporters Are Determinants of Oxaliplatin Cytotoxicity
2006
Mechanisms of Viral Membrane Fusion and Its Inhibition
2001
Multihistology, Target-Driven Pilot Trial of Oral Topotecan as an Inhibitor of Hypoxia-Inducible Factor-1α in Advanced Solid Tumors
2011
An Akt/Hypoxia-Inducible Factor-1α/Platelet-Derived Growth Factor-BB Autocrine Loop Mediates Hypoxia-Induced Chemoresistance in Liver Cancer Cells and Tumorigenic Hepatic Progenitor Cells
2009
A Small-Molecule Modulator of Poly-α2,8-Sialic Acid Expression on Cultured Neurons and Tumor Cells
2001 StandoutScienceNobel
Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression
2010 StandoutNobel
Hypoxia‐inducible factors: coupling glucose metabolism and redox regulation with induction of the breast cancer stem cell phenotype
2016 StandoutNobel
Cyanovirin-N Inhibits AIDS Virus Infections in Vaginal Transmission Models
2004
Genetic evidence for a tumor suppressor role of HIF-2α
2005
Prognostic significance of Hypoxia-Inducible Factor 1 alpha(HIF-1alpha) expression in serous ovarian cancer: an immunohistochemical study
2008
Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition
2012
Molecular mechanisms mediating metastasis of hypoxic breast cancer cells
2012 StandoutNobel
Cancer–stromal cell interactions mediated by hypoxia-inducible factors promote angiogenesis, lymphangiogenesis, and metastasis
2012 StandoutNobel
On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models
2016 StandoutNatureNobel
Aminoflavone, a Ligand of the Aryl Hydrocarbon Receptor, Inhibits HIF-1α Expression in an AhR-Independent Fashion
2010
Hallmarks of Cancer: The Next Generation
2011 Standout
Contrasting Properties of Hypoxia-Inducible Factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-Associated Renal Cell Carcinoma
2005 StandoutNobel
HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression
2011
Hypoxia-Inducible Factors in Physiology and Medicine
2012 StandoutNobel
HIF‐1α and HIF‐2α have divergent roles in colon cancer
2008
A Novel Trinuclear Platinum Complex Overcomes Cisplatin Resistance in an Osteosarcoma Cell System
1999
A gene expression database for the molecular pharmacology of cancer
2000 Nobel
Indolocarbazole poisons of human topoisomerase I: Regioisomeric analogues of ED-110
1999
Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway
2004
Synthetic Lethal Screening Identifies Compounds Activating Iron-Dependent, Nonapoptotic Cell Death in Oncogenic-RAS-Harboring Cancer Cells
2008
Dichloroacetate reverses the hypoxic adaptation to bevacizumab and enhances its antitumor effects in mouse xenografts
2013
Multisite and Multivalent Binding between Cyanovirin-N and Branched Oligomannosides
2002
Systematic variation in gene expression patterns in human cancer cell lines
2000 Standout
Cyanovirin-N binds to the viral surface glycoprotein, GP1,2 and inhibits infectivity of Ebola virus
2003
Autocrine TNFα Signaling Renders Human Cancer Cells Susceptible to Smac-Mimetic-Induced Apoptosis
2007
Site-specific Discrimination by Cyanovirin-N for α-Linked Trisaccharides Comprising the Three Arms of Man8 and Man9
2002
Targeting HIF-1 for cancer therapy
2003 StandoutNobel
Targeting hypoxia cell signaling for cancer therapy
2007
Combinatorial and computational challenges for biocatalyst design
2001 StandoutNatureNobel
Energy metabolism in tumor cells
2007
Targeting the glycans of gp120: a novel approach aimed at the Achilles heel of HIV
2005
A Simple Screening System for Anti-HIV Drugs: Syncytium Formation Assay Using T-Cell Line Tropic and Macrophage Tropic HIV env Expressing Cell Lines. Establishment and Validation.
2001 StandoutNobel
HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations
2013 StandoutNobel
Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation
2012 StandoutNatureNobel
Metronomic treatment of malignant glioma xenografts with irinotecan (CPT-11) inhibits angiogenesis and tumor growth
2010
Actinohivin, a Novel Anti-HIV Protein from an Actinomycete That Inhibits Syncytium Formation: Isolation, Characterization, and Biological Activities
2001 StandoutNobel
When Checkpoints Fail
1997 StandoutNobel
DNA cleavage assay for the identification of topoisomerase I inhibitors
2008
Tumor Cell Metabolism: Cancer's Achilles' Heel
2008 Standout
Reversible Inactivation of HIF-1 Prolyl Hydroxylases Allows Cell Metabolism to Control Basal HIF-1
2005
The Hallmarks of Cancer
2000 Standout
Expression of Vascular Endothelial Growth Factor Receptor 1 in Bone Marrow-derived Mesenchymal Cells Is Dependent on Hypoxia-inducible Factor 1
2006 StandoutNobel
Tie2-dependent knockout of HIF-1 impairs burn wound vascularization and homing of bone marrow-derived angiogenic cells
2011 StandoutNobel
Safety concerns for the potential use of cyanovirin-N as a microbicidal anti-HIV agent
2008
A New Weapon for Attacking Tumor Blood Vessels
2008 StandoutNobel
Nonclassical Platinum Antitumor Agents: Perspectives for Design and Development of New Drugs Complementary to Cisplatin
1993
Apoptosis induction and inhibition of H-ras overexpression by novel trans-[PtCl2(isopropylamine)(amine′)] complexes1This work was presented at the 8th International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, held in Oxford, UK, 28–31 March 1999.1
1999
Targeting HIF1α Eliminates Cancer Stem Cells in Hematological Malignancies
2011
Cyanovirin-N Defines a New Class of Antiviral Agent Targeting N-Linked, High-Mannose Glycans in an Oligosaccharide-Specific Manner
2001
Exploiting tumour hypoxia in cancer treatment
2004 Standout
Apoptosis Induction and DNA Interstrand Cross-Link Formation by Cytotoxictrans-[PtCl2(NH(CH3)2)(NHCH(CH3)2)]: Cross-Linking between d(G) and Complementary d(C) within Oligonucleotide Duplexes
2002
Solution Structure of a Cyanovirin-N:Manα1-2Manα Complex
2001
Synergism through direct covalent bonding between agents: A strategy for rational design of chemotherapeutic combinations
1990
Regulation of Ferroptotic Cancer Cell Death by GPX4
2014 Standout
The first synthesis of clausenamine-A and cytotoxic activities of three biscarbazole analogues against cancer cells
2000
Membrane Fusion
2003 StandoutNobel
Paracrine Induction of HIF by Glutamate in Breast Cancer: EglN1 Senses Cysteine
2016 StandoutNobel
Hypoxia-mediated drug resistance: Novel insights on the functional interaction of HIFs and cell death pathways
2011
Hypoxia signalling in cancer and approaches to enforce tumour regression
2006 Nature
3-O-isobutyrylkinamycin C and 4-deacetyl-4-O-isobutyrylkinamycin C, new antibiotics produced by a Saccharothrix species.
1989
Hypoxia Rescues Frataxin Loss by Restoring Iron Sulfur Cluster Biogenesis
2019 StandoutNobel
Molecular portraits of human breast tumours
2000 StandoutNature
YC-1 inhibits HIF-1 expression in prostate cancer cells: contribution of Akt/NF-κB signaling to HIF-1α accumulation during hypoxia
2007
Current lead natural products for the chemotherapy of human immunodeficiency virus (HIV) infection
2000
Regulation of HIF-1α Stability through S-Nitrosylation
2007
Hypoxia: A key regulator of angiogenesis in cancer
2007
HIF1α Induces the Recruitment of Bone Marrow-Derived Vascular Modulatory Cells to Regulate Tumor Angiogenesis and Invasion
2008
Geldanamycin inhibits migration of glioma cells in vitro: A potential role for hypoxia‐inducible factor (HIF‐1α) in glioma cell invasion
2003
Control of TH17/Treg Balance by Hypoxia-Inducible Factor 1
2011 StandoutNobel
Protein-Linked DNA Strand Breaks Induced by NSC 314622, a Novel Noncamptothecin Topoisomerase I Poison
1998
HIF-1 Regulates Cytochrome Oxidase Subunits to Optimize Efficiency of Respiration in Hypoxic Cells
2007 StandoutNobel
Opportunities in discovery and delivery of anticancer drugs targeting mitochondria and cancer cell metabolism☆
2009
Actinohivin, a novel anti-human immunodeficiency virus protein from an actinomycete, inhibits viral entry to cells by binding high-mannose type sugar chains of gp120
2004 StandoutNobel
Negative Regulation of Hypoxic Responses via Induced Reptin Methylation
2010 StandoutNobel
A protein expression database for the molecular pharmacology of cancer
1997
Targeting the glycans of glycoproteins: a novel paradigm for antiviral therapy
2007
ED‐110, a Novel Indolocarbazole, Prevents the Growth of Experimental Tumors in Mice
1993
Allosteric inhibition of hypoxia inducible factor-2 with small molecules
2013
DNA interactions of new antitumor platinum complexes with trans geometry activated by a 2-metylbutylamine or sec-butylamine ligand
2003
Oxygen Sensing, Homeostasis, and Disease
2011 StandoutNobel
Cancer-related inflammation
2008 StandoutNature
Pyruvate Kinase M2 Is a PHD3-Stimulated Coactivator for Hypoxia-Inducible Factor 1
2011 StandoutNobel
Topoisomerase I inhibitors: camptothecins and beyond
2006 Standout
Cytotoxicity of a new IMP dehydrogenase inhibitor, benzamide riboside, to human myelogenous leukemia K562 cells
1992
Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
2009 StandoutNobel
Evaluation of HIF-1 inhibitors as anticancer agents
2007 StandoutNobel
Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy
2012 StandoutNobel
Reversing Hypoxic Cell Chemoresistance in Vitro Using Genetic and Small Molecule Approaches Targeting Hypoxia Inducible Factor-1
2005
Current status of the development of trans-platinum antitumor drugs
2000
New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening
1990 Standout
Prolyl Hydroxylase Domain Inhibitors: A Route to HIF Activation and Neuroprotection
2009
Phenanthriplatin, a monofunctional DNA-binding platinum anticancer drug candidate with unusual potency and cellular activity profile
2012
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Clues from cell metabolism
2010 StandoutNatureNobel
Life with Oxygen
2007 StandoutScienceNobel
The Von Hippel-Lindau Tumor Suppressor Gene and Kidney Cancer
2004 StandoutNobel
Search and Discovery Strategies for Biotechnology: the Paradigm Shift
2000
Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth
2008 StandoutNobel
The Mannose-Dependent Epitope for Neutralizing Antibody 2G12 on Human Immunodeficiency Virus Type 1 Glycoprotein gp120
2002
Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen
1995 Standout
ANTICANCER ACTIVITY OF PYRIPLATIN, A MONOFUNCTIONAL CATIONIC PLATINUM(II) COMPOUND, IN HUMAN CANCER CELLS
2011
Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data
1991
Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1.
2003 StandoutNobel
Identification of Simple Compounds with Microtubule-Binding Activity That Inhibit Cancer Cell Growth with High Potency
2011
Design of antineoplastic agents on the basis of the “2‐phenyl‐naphthalene‐type” structural pattern. 3. synthesis and biological activity evaluation of 5H‐benzo[b]naphtho‐[2,3‐d]pyrrole‐6,11‐dione derivatives
1996
Meeting Report: Exploiting the Tumor Microenvironment for Therapeutics
2006 StandoutNobel
Third row transition metals for the treatment of cancer
2015
DNA Topoisomerase I Inhibitors: Chemistry, Biology, and Interfacial Inhibition
2009 Standout
Effects of Aging and Hypoxia-Inducible Factor-1 Activity on Angiogenic Cell Mobilization and Recovery of Perfusion After Limb Ischemia
2007 StandoutNobel
Staurosporine and ent-Staurosporine: The First Total Syntheses, Prospects for a Regioselective Approach, and Activity Profiles1
1996
Modulatory profiling identifies mechanisms of small molecule-induced cell death
2011
Inhibiting Hypoxia-Inducible Factor 1 for Cancer Therapy
2006
Class II Histone Deacetylases Are Associated with VHL-Independent Regulation of Hypoxia-Inducible Factor 1α
2006
Both Microtubule-Stabilizing and Microtubule-Destabilizing Drugs Inhibit Hypoxia-Inducible Factor-1α Accumulation and Activity by Disrupting Microtubule Function
2005
Adaptive and Maladaptive Cardiorespiratory Responses to Continuous and Intermittent Hypoxia Mediated by Hypoxia-Inducible Factors 1 and 2
2012 StandoutNobel
Design, Synthesis, and Biological Evaluation of 14-Substituted Aromathecins as Topoisomerase I Inhibitors
2008
Mutational Pathways, Resistance Profile, and Side Effects of Cyanovirin Relative to Human Immunodeficiency Virus Type 1 Strains with N-Glycan Deletions in Their gp120 Envelopes
2006
The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives
2009
cis -Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospects
2008 StandoutNobel
Artificial ligand binding within the HIF2α PAS-B domain of the HIF2 transcription factor
2009
Endothelial protein C receptor (CD201) explicitly identifies hematopoietic stem cells in murine bone marrow
2005
Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas.
1995
Selective Interactions of the Human Immunodeficiency Virus-Inactivating Protein Cyanovirin-N with High-Mannose Oligosaccharides on gp120 and Other Glycoproteins
2001
Regulation of the Chemokine Receptor CXCR4 by Hypoxia
2003
Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1.
2003 StandoutNobel
In vivo hematopoietic stem cell modification by mRNA delivery
2023 StandoutScienceNobel
Dynamic Change of Chromatin Conformation in Response to Hypoxia Enhances the Expression of GLUT3 (SLC2A3) by Cooperative Interaction of Hypoxia-Inducible Factor 1 and KDM3A
2012
Neural Computing in Cancer Drug Development: Predicting Mechanism of Action
1992 StandoutScienceNobel
Mechanism by which the lectin actinohivin blocks HIV infection of target cells
2009 StandoutNobel
In Vitro Anticancer Activity ofcis-Diammineplatinum(II) Complexes with β-Diketonate Leaving Group Ligands
2012
Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecin-resistant topoisomerases I.
2003 Nobel
Understanding and improving platinum anticancer drugs--phenanthriplatin.
2014
Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline.
1995 StandoutNobel
Modulating Hypoxia-Inducible Transcription by Disrupting the HIF-1–DNA Interface
2007
Isolation and Synthesis of Biologically Active Carbazole Alkaloids
2002 Standout
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
2009 StandoutScience
A RNA antagonist of hypoxia-inducible factor-1α, EZN-2968, inhibits tumor cell growth
2008
Engineering Chemical Reactivity on Cell Surfaces Through Oligosaccharide Biosynthesis
1997 StandoutScienceNobel
Polysialic acid on the neural cell adhesion molecule correlates with expression of polysialyltransferases and promotes neuroblastoma cell growth.
1998
Synthesis of Cytotoxic Indenoisoquinoline Topoisomerase I Poisons
1999
The Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2G12 Recognizes a Cluster of α1→2 Mannose Residues on the Outer Face of gp120
2002
Evaluating Hypoxia-Inducible Factor-1α as a Cancer Therapeutic Target via Inducible RNA Interference In vivo
2005
Mannose-Specific Plant Lectins from the Amaryllidaceae Family Qualify as Efficient Microbicides for Prevention of Human Immunodeficiency Virus Infection
2004
Works of Robert H. Shoemaker being referenced
Differential Involvement of Vascular Endothelial Growth Factor in the Survival of Hypoxic Colon Cancer Cells
2008
Echinomycin, a Small-Molecule Inhibitor of Hypoxia-Inducible Factor-1 DNA-Binding Activity
2005
Cell Type–Specific, Topoisomerase II–Dependent Inhibition of Hypoxia-Inducible Factor-1α Protein Accumulation by NSC 644221
2007
Antiangiogenic agents and HIF-1 inhibitors meet at the crossroads
2009
A high-throughput screen for identification of molecular mimics of Smac/DIABLO utilizing a fluorescence polarization assay
2003
Feasibility of a High-Flux Anticancer Drug Screen Using a Diverse Panel of Cultured Human Tumor Cell Lines
1991 Standout
Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines
1996
Display and Analysis of Patterns of Differential Activity of Drugs Against Human Tumor Cell Lines: Development of Mean Graph and COMPARE Algorithm
1989
Expression of the vascular endothelial cell protein C receptor in epithelial tumour cells
2002
Analysis of Sequence Requirements for Biological Activity of Cyanovirin-N, a Potent HIV(Human Immunodeficiency Virus)-Inactivating Protein
1997
Recombinant Production of Cyanovirin-N, a Potent Human Immunodeficiency Virus-Inactivating Protein Derived from a Cultured Cyanobacterium
1998
Comparison of In Vitro Anticancer-Drug-Screening Data Generated With a Tetrazolium Assay Versus a Protein Assay Against a Diverse Panel of Human Tumor Cell Lines
1990
Anticancer Specificity of Some Ellipticinium Salts against Human Brain Tumors in vitro
1994
Data mining of NCI's anticancer screening database reveals mitochondrial complex I inhibitors cytotoxic to leukemia cell lines
2006
The NCI60 human tumour cell line anticancer drug screen
2006 Standout
Targeting Topoisomerase 1 to inhibit Hypoxia Inducible Factor 1
2004
Targeting the PAS-A Domain of HIF-1α for Development of Small Molecule Inhibitors of HIF-1
2006
Schedule-dependent Inhibition of Hypoxia-inducible Factor-1α Protein Accumulation, Angiogenesis, and Tumor Growth by Topotecan in U251-HRE Glioblastoma Xenografts
2004
Targeting topoisomerase I to inhibit hypoxia inducible factor 1.
2004
Hypoxic induction of an HIF-1α–dependent bFGF autocrine loop drives angiogenesis in human endothelial cells
2005
Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines.
1988 Standout
Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway.
2002
Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.
1988 Standout
Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition
2009
Application of a human tumor colony-forming assay to new drug screening.
1985
Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development
1997
Topoisomerase I-Mediated Inhibition of Hypoxia-Inducible Factor 1
2004